Nature Communications-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2022-01-28 hezhixin

偏重的研究方向：综合学科
经验分享：已经under consideration9天了，还有希望吗？？兄弟们？

495 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2022-05-14 cindichaw

正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。

583 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2023-01-04 ms6000000798925478 来自广东省

偏重的研究方向：消化;单细胞
经验分享：1-1 submitted
1-3 editor assigned
1-3 manuscript under consideration
1-4 contacting potential reviewers
希望有个好结果

193 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2023-02-25 ms5000001717908182 来自北京

2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？

146 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2023-02-13 ms6000000798925478 来自广东省

偏重的研究方向：消化
经验分享：Stage Start Date
Manuscript under consideration 29th January 23
19th January 23
Manuscript under consideration 4th January 23
Contacting Potential Reviewers 4th January 23
Manuscript under consideration 3rd January 23
Editor Assigned 3rd January 23
Manuscript submitted 1st January 23
各位大佬帮忙看看，这是啥情况，投出去42天了

131 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2016-04-26 rightherely

我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？

539 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2023-02-02 做梦也想sci 来自山东省

偏重的研究方向：医学
经验分享：请问各位前辈NC收临床的随机对照研究吗？

102 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2023-02-02 做梦也想sci 来自山东省

偏重的研究方向：外科;营养
经验分享：请问各位前辈NC接收纯临床的RCT吗？

79 0

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2021-04-18 victorywangz

审稿速度:12.0 | 投稿命中率:50.0
经验分享：Manuscript under consideration 23rd March 21
Contacting Potential Reviewers 23rd March 21
Manuscript under consideration 2nd March 21
Editor Assigned 2nd March 21
Manuscript submitted 27th February 21
Submission in process 27th February 21

361 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=495, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219552, encodeId=908d1219552c6, content=正在修稿第三篇。感觉确实不是顶尖的，比不上NG，NM，NCB等大子刊。但工作量不小，每个工作大约要耗费30-100万经费，2-5年时间。创新性也是有相当要求的。有的被其秒拒的工作也很快被cancer res等接收。非生物医学领域不清楚，希望保持不要放水。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=583, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sat May 14 11:53:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108823, encodeId=a508210882371, content=偏重的研究方向：消化;单细胞 经验分享：1-1 submitted 1-3 editor assigned 1-3 manuscript under consideration 1-4 contacting potential reviewers 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Jan 04 20:22:06 CST 2023, time=2023-01-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116415, encodeId=740a211641509, content=2021年11月底投稿，到现在都没有审稿意见，请教各位正常吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7e05508048, createdName=ms5000001717908182, createdTime=Sat Feb 25 14:17:38 CST 2023, time=2023-02-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2114325, encodeId=d8bd211432520, content=偏重的研究方向：消化 经验分享：Stage Start Date Manuscript under consideration 29th January 23 19th January 23 Manuscript under consideration 4th January 23 Contacting Potential Reviewers 4th January 23 Manuscript under consideration 3rd January 23 Editor Assigned 3rd January 23 Manuscript submitted 1st January 23 各位大佬帮忙看看，这是啥情况，投出去42天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Mon Feb 13 00:49:31 CST 2023, time=2023-02-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=521732, encodeId=60ac521e3299, content=我的稿件状态是“manuscript under consideration”，但编辑给我写信说是已经送外审了，什么意思？manuscript under consideration就是已经外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=539, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4951630181, createdName=rightherely, createdTime=Tue Apr 26 10:48:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112750, encodeId=96382112e5014, content=偏重的研究方向：医学 经验分享：请问各位前辈NC收临床的随机对照研究吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:46:15 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112745, encodeId=c5ce2112e4537, content=偏重的研究方向：外科;营养 经验分享：请问各位前辈NC接收纯临床的RCT吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16956388344, createdName=做梦也想sci, createdTime=Thu Feb 02 15:27:17 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=958003, encodeId=b2d3958003e4, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：Manuscript under consideration 23rd March 21 Contacting Potential Reviewers 23rd March 21 Manuscript under consideration 2nd March 21 Editor Assigned 2nd March 21 Manuscript submitted 27th February 21 Submission in process 27th February 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7c45481669, createdName=victorywangz, createdTime=Sun Apr 18 12:11:47 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590524, encodeId=ebf35905248b, content=挺好 nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表: 送审以后stage栏为空, beContent=nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c69e2106000, createdName=zhiaoyang, createdTime=Sat May 09 00:00:00 CST 2020, time=2020-05-09, status=1, ipAttribution=)]

2020-05-09 zhiaoyang

挺好 nianhuaifeiai 2019-12-13 发表::
送审以后stage栏为空nianhuaifeiai 2019-12-13 00:00:00 发表:
送审以后stage栏为空

nianhuaifeiai 2019-12-13 发表:: 送审以后stage栏为空

344 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务